FDA ad policy reform supported by ex-FDAers, other former government officials at GWU forum.
FDA AD POLICY INHIBITS FILING OF SUPPLEMENTS, EX-FDAer Jur Strobos, MD, now with the D.C. firm Greenberg, Traurig, states in a policy paper to be published in January in the Food & Drug Law Institute journal. Strobos, formerly FDA policy research director, notes in a summary of his paper that one rationale offered by defenders of FDA's strict limits on dissemination of off-label use information is that "no company would ever file a supplement for a new indication" if they could claim the new indication in advertising. In fact, Strobos contends, "current policy actually inhibits filing of supplements, unless the potential purchaser that must be targeted can only be reached by direct advertising, because new markets are an avenue for information transfer."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth